Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENTA Stock Forecast 2025-2026
$14.60
Current Price
$421.25M
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ENTA Price Targets
+91.8%
To High Target of $28.00
+37.0%
To Median Target of $20.00
-24.7%
To Low Target of $11.00
ENTA Price Momentum
+3.4%
1 Week Change
+32.8%
1 Month Change
+82.5%
1 Year Change
+153.9%
Year-to-Date Change
-4.8%
From 52W High of $15.34
+257.0%
From 52W Low of $4.09
📊 TOP ANALYST CALLS
Did ENTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Enanta is one of their latest high-conviction picks.
Latest ENTA Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, ENTA has a bullish consensus with a median price target of $20.00 (ranging from $11.00 to $28.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $14.60, the median forecast implies a 37.0% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ed Arce at WestPark Capital, projecting a 91.8% upside. Conversely, the most conservative target is provided by Eric Joseph at JP Morgan, suggesting a 24.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENTA Analyst Ratings
7
Buy
1
Hold
0
Sell
ENTA Price Target Range
Low
$11.00
Average
$20.00
High
$28.00
Current: $14.60
Latest ENTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | JP Morgan | Anupam Rama | Overweight | Initiates | $17.00 |
| Oct 1, 2025 | Jefferies | Buy | Upgrade | $N/A | |
| Sep 30, 2025 | WestPark Capital | Ed Arce | Buy | Maintains | $28.00 |
| Sep 15, 2025 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $12.00 |
| Sep 2, 2025 | WestPark Capital | Ed Arce | Buy | Initiates | $24.00 |
| Aug 12, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $25.00 |
| Jul 28, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $20.00 |
| Jun 3, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $24.00 |
| May 14, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Feb 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $18.00 |
| Feb 11, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $21.00 |
| Dec 24, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $18.00 |
| Nov 26, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $21.00 |
| Nov 26, 2024 | Baird | Brian Skorney | Outperform | Maintains | $20.00 |
| Oct 10, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $27.00 |
| Oct 9, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $22.00 |
| Sep 27, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $22.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $27.00 |
| Aug 6, 2024 | JP Morgan | Eric Joseph | Underweight | Maintains | $10.00 |
| May 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $27.00 |
Enanta Pharmaceuticals Inc. (ENTA) Competitors
The following stocks are similar to Enanta based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enanta Pharmaceuticals Inc. (ENTA) Financial Data
Enanta Pharmaceuticals Inc. has a market capitalization of $421.25M with a P/E ratio of -3.8x. The company generates $65.32M in trailing twelve-month revenue with a -125.4% profit margin.
Revenue growth is +3.5% quarter-over-quarter, while maintaining an operating margin of -121.6% and return on equity of -84.6%.
Valuation Metrics
Market Cap
$421.25M
Enterprise Value
$433.59M
P/E Ratio
-3.8x
PEG Ratio
0.1x
Price/Sales
6.5x
Growth & Margins
Revenue Growth (YoY)
+3.5%
Gross Margin
N/A
Operating Margin
-121.6%
Net Margin
-125.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+44.8%
Current Ratio
4.2x
Debt/Equity
310.7x
ROE
-84.6%
ROA
-16.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enanta Pharmaceuticals Inc. (ENTA) Business Model
About Enanta Pharmaceuticals Inc.
What They Do
Develops small molecule drugs for viral infections.
Business Model
The company focuses on drug discovery and development, particularly for viral infections and liver diseases. Enanta generates revenue through collaborations with major pharmaceutical companies, which often lead to the commercialization of its innovative treatments, notably for hepatitis C.
Additional Information
Enanta Pharmaceuticals is headquartered in Watertown, Massachusetts, and has a strong pipeline of therapies aimed at addressing significant global health issues. The company operates in a competitive biotech sector, utilizing its expertise in medicinal chemistry and drug development to meet unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
131
CEO
Dr. Jay R. Luly Ph.D.
Country
United States
IPO Year
2013
Website
www.enanta.comEnanta Pharmaceuticals Inc. (ENTA) Latest News & Analysis
Latest News
Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade
16 days ago
Quick Summary
Enanta Pharmaceuticals (ENTA) has a consensus price target suggesting a 44.9% upside potential. Recent earnings estimate revisions indicate possible near-term gains.
Why It Matters
The 44.9% upside potential for Enanta Pharmaceuticals suggests strong growth expectations, and rising earnings estimates may indicate positive momentum, signaling possible stock appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) reported Q4 and fiscal year results for 2025, noting progress in virology and immunology, including positive data from the RSVHR study.
Why It Matters
Enanta Pharmaceuticals' positive topline data from the RSVHR study indicates potential advances in their drug development, which could enhance market value and attract investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (ENTA) maintains a "Buy" rating after positive secondary endpoints for zelicapavir in RSV. Strong pipeline and cash position extend development through fiscal 2029.
Why It Matters
Enanta Pharmaceuticals' strong pipeline and extended cash runway bolster investor confidence despite missing primary endpoints, indicating potential for future growth and stability.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) will participate in investor conferences in November and December, including a fireside chat at the Jefferies London Global Healthcare Conference on November 18, 2025.
Why It Matters
Enanta Pharmaceuticals' participation in key investor conferences signals potential insights into its drug development progress, which could influence stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals will present new data on its RSV treatments, zelicapavir and EDP-323, at IDWeek 2025 from October 19-22.
Why It Matters
New data on Enanta Pharmaceuticals' drug candidates for RSV could impact their market position and investor sentiment, influencing stock performance and future funding opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals will present data on its RSV treatments, zelicapavir and EDP-323, at IDWeek 2025 from October 19-22.
Why It Matters
Enanta Pharmaceuticals' upcoming presentation on its RSV treatments could signal progress in drug development, potentially impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ENTA Stock
What is Enanta Pharmaceuticals Inc.'s (ENTA) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Enanta Pharmaceuticals Inc. (ENTA) has a median price target of $20.00. The highest price target is $28.00 and the lowest is $11.00.
Is ENTA stock a good investment in 2026?
According to current analyst ratings, ENTA has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENTA stock?
Wall Street analysts predict ENTA stock could reach $20.00 in the next 12 months. This represents a 37.0% increase from the current price of $14.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enanta Pharmaceuticals Inc.'s business model?
The company focuses on drug discovery and development, particularly for viral infections and liver diseases. Enanta generates revenue through collaborations with major pharmaceutical companies, which often lead to the commercialization of its innovative treatments, notably for hepatitis C.
What is the highest forecasted price for ENTA Enanta Pharmaceuticals Inc.?
The highest price target for ENTA is $28.00 from Ed Arce at WestPark Capital, which represents a 91.8% increase from the current price of $14.60.
What is the lowest forecasted price for ENTA Enanta Pharmaceuticals Inc.?
The lowest price target for ENTA is $11.00 from Eric Joseph at JP Morgan, which represents a -24.7% decrease from the current price of $14.60.
What is the overall ENTA consensus from analysts for Enanta Pharmaceuticals Inc.?
The overall analyst consensus for ENTA is bullish. Out of 15 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are ENTA stock price projections?
Stock price projections, including those for Enanta Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 3:50 PM UTC